Trade Sarepta Therapeutics, Inc. - SRPT CFD

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Latest shares articles

Amazon Q2 Earnings Preview: tariffs, mixed demand and AWS under scrutiny
Signs of further AI monetisation could push Amazon shares towards all time highs.
14:02, 31 July 2025
Forex CFDs: Understanding currency forwards vs spot markets
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
13:08, 31 July 2025
US labour data could give more context to a stronger-than-expected GDP in Q2
The US labour market is expected to have cooled in July as a stronger-than-expected Q2 GDP print surprised markets
12:17, 31 July 2025
Crypto CFDs: Popular cryptocurrencies for trading
Crypto CFDs: Popular cryptocurrencies for trading
Discover which cryptocurrencies are trending for CFD trading in 2025 – from bitcoin to newly listed coins like SUI and PEPE.
10:21, 31 July 2025

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2025-07-01
Victor Flemming Nandwa Søder

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-07-01
Perry Reineke

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-06-29
proinpro

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

2025-06-27
Gio Gvazava

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-22
Douglas

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-22
Jean A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-19
foobarbeer

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-06-19
Casaubon70

Love the TV integration. Makes traders life smooth and comfortable.

2025-06-19
dgogidze7

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-05-30
Brigman

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-05-24
Radioilluminati

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-04-29
dmjnoor

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-05-20
GemzT

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-03-24
Debbie P

The best trading company I've found so far and so easy to use.

2025-02-06
Nouman Butt

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading CFDs